[Skip to Content]
[Skip to Content Landing]
Article
June 1990

MK-927, A Topical Carbonic Anhydrase Inhibitor: Dose Response and Reproducibility

Author Affiliations

From the Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY (Drs Serie, Lustgarten, Camras, and Podos), and Merck, Sharp & Dohme Research Laboratories, West Point, Pa (Dr Lippa and Ms Panebianco).

Arch Ophthalmol. 1990;108(6):838-841. doi:10.1001/archopht.1990.01070080080039
Abstract

• We investigated the dose-response and reproducibility of the intraocular pressure-lowering effect of MK-927 in ocular hypertensive patients. Patients were enrolled until at least 8 "marked responders" (peak reduction in intraocular pressure comparing the MK-927-treated eye with the placebo-treated eye ≥6 mm Hg) and 7 "mild responders" (peak reduction in intraocular pressure comparing the MK-927-treated eye with the placebo-treated eye ≤3 mm Hg) were identified. In part A, 27 patients received one drop of 2% MK-927 in one eye (baseline mean ± SEM intraocular pressure, 28.0 ±1.0 mm Hg) and placebo in the contralateral eye. Intraocular pressure was measured at baseline and 1, 2, 3, 4, and 6 hours. Maximum reduction in intraocular pressure was 4.0 ±0.8 mm Hg at 3 hours, with a duration of 4 hours. Ten patients were identified as marked responders and 7 as mild responders. In part B, 8 of the marked responders entered a four-period crossover study and received 2%, 0.5%, and 0.125% MK-927 and placebo in the same treated eye as in part A, and placebo in the contralateral eye. The 7 mild responders in part C received 2% MK-927 in a similar fashion as in part A. MK-927 in concentrations of 0.125% and 0.5% had little or no effect on intraocular pressure in patients with a marked response to 2% MK-927. Within-patient variability in peak response to single doses of 2% MK-927 was substantial (coefficient of variation of 0.3 and 0.5 for marked responder and mild responder groups, respectively).

×